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Wnt Signaling Deregulation in the
Aging and Alzheimer’s Brain
Ernest Palomer*†, Johanna Buechler† and Patricia C. Salinas*
Department of Cell and Developmental Biology, University College London, London, United Kingdom
Growing evidence suggests that synaptic signaling is compromised in the aging
brain and in Alzheimer’s disease (AD), contributing to synaptic decline. Wnt signaling
is a prominent pathway at the synapse and is required for synaptic plasticity and
maintenance in the adult brain. In this review, we summarize the current knowledge
on deregulation of Wnt signaling in the context of aging and AD. Emerging studies
suggest that enhancing Wnt signaling could boost synaptic function during aging, and
ameliorate synaptic pathology in AD. Although further research is needed to determine
the precise contribution of deficient Wnt signaling to AD pathogenesis, targeting Wnt
signaling components may provide novel therapeutic avenues for synapse protection or
restoration in the brain.
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INTRODUCTION
Wnt signaling was originally discovered as a tumorigenic pathway in the early 1980s. Almost four
decades later, this prominent pathway has been implicated in numerous cellular processes from
early embryonic development to tissue homeostasis. This signaling cascade is also linked to a variety
of diseases, from cancer to bone and cardiovascular diseases. In the nervous system, Wnt signaling
plays a vital role from early patterning of the nervous system to higher functions including synaptic
plasticity and memory in the adult brain. In this review, we will focus on new studies indicating a
deregulation of the Wnt signaling pathway in the aging brain and Alzheimer’s disease (AD).
Alzheimer’s Disease
Alzheimer’s disease is a devastating neurodegenerative disorder that accounts for two thirds of
all dementia cases, and is characterized by progressive cognitive impairment and memory loss
leading to difficulties in the performance of daily tasks (Apostolova, 2016). The AD brain displays
extracellular Amyloid beta (Aß) deposition, intracellular Tau aggregates (neurofibrillary tangles),
and widespread neuronal death at late AD stages. However, synapse loss is the prominent event
in early stages of AD and represents the best pathological correlate of cognitive decline in patients
(Terry et al., 1991). Current models propose that synaptic dysfunction and degeneration in AD
are initiated by oligomers of Aß, a key pathogenic molecule, which negatively regulates signaling
pathways that are crucial for synaptic function and stability (Forner et al., 2017). Consistent with
this view, increasing evidence suggests that Aß triggers deregulation of Wnt signaling, resulting in
the dampening of this important cascade at the synapse. These changes in the Wnt pathway could
contribute to synapse dysfunction and degeneration, thereby promoting the progression of AD.
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Wnt Signaling Pathway
Wnt proteins are a family of secreted lipoproteins that activate
different intracellular signaling pathways by binding to several
receptors and co-receptors at the cell surface. Three major
Wnt signaling pathways have been described: canonical Wnt/ß-
catenin, planar cell polarity (PCP), and Wnt/Ca2+ pathways,
which lead to changes in gene expression and/or cytoskeleton
reorganization. The most extensively studied cascade is the
canonical Wnt pathway that controls the expression of Wnt
target genes by stabilizing cytoplasmic ß-catenin and by
inducing the reorganization of the cellular cytoskeleton (Nusse
and Clevers, 2017). In absence of Wnt ligands, ß-catenin is
phosphorylated by Gsk3ß and CK1 in the cytoplasm, leading
to its degradation (Figure 1A; Nusse and Clevers, 2017).
Upon binding of Wnt ligands to their receptors Frizzled and
co-receptors LRP5/6, the scaffold proteins Disheveled (Dvl)
and Axin are recruited to form a signalosome at the cell
membrane. This in turn allows ß-catenin accumulation in
the cytoplasm and its translocation to the nucleus, where
it associates with TCF/LEF and other co-factors to regulate
Wnt target gene transcription (Figure 1B; Nusse and Clevers,
2017). The Wnt PCP pathway leads to transcriptional changes
and cytoskeleton reorganization upon Wnt ligand binding
to Frizzled receptors, without the requirement of Wnt co-
receptors LRP5/6 (Seifert and Mlodzik, 2007). This signaling
cascade activates the small GTPases RhoA and Rac1, which
in turn activate the kinases ROCK and JNK, respectively
(Figure 1C; Seifert and Mlodzik, 2007). The third pathway
is the Wnt/Ca2+ cascade, in which binding of Wnts to
Frizzled receptors leads to phospholipase C (PLC) activation,
release of Ca2+ from intracellular stores and activation of
CaMKII and PKC, resulting in transcriptional changes and actin
remodeling (De, 2011).
Wnt Signaling at the Mature Synapse
Wnt signaling has been implicated in axonal pathfinding,
dendritogenesis, synapse formation, synaptic plasticity, and
maintenance (Budnik and Salinas, 2011; Dickins and Salinas,
2013; McLeod and Salinas, 2018). A fine balance of canonical and
non-canonical PCP Wnt signaling is required for maintaining
mature synapses. Decreased levels of canonical Wnt signaling
with the concomitant activation of the PCP pathway leads
to synapse disassembly (Marzo et al., 2016; Sellers et al.,
2018). In addition, canonical and non-canonical Wnt pathways
play a role in synaptic plasticity at the mature synapse.
For example, different Wnt proteins are involved in early
or late phases of long-term potentiation (LTP). In vivo
studies show that canonical Wnt signaling is required for
the early phase of LTP and also sufficient to enhance it
(Ivanova et al., 2017). Non-canonical Wnt signaling pathways
have been implicated in both early and late phases of
LTP. Wnt7a/b through its receptor frizzled 7, participates
in early LTP phases by promoting AMPAR recruitment
at the synapses in vitro (McLeod et al., 2018). As this
process is CaMKII dependent, it is likely to be due to
the activation of Wnt/Ca2+ pathway. In addition, Wnt5a
regulates basal NMDAR currents and influences late phase
of LTP by activating the Wnt PCP pathway in hippocampal
slices (Cerpa et al., 2011). Altogether, these studies demonstrate
that canonical and non-canonical Wnt signaling are relevant
pathways at the mature synapse.
WNT SIGNALING AND AGING
Reduced synaptic strength and function occur during normal
aging (Morrison and Baxter, 2012; Petralia et al., 2014).
Age is the biggest risk factor for late-onset AD, as growing
synaptic vulnerability may increase the susceptibility of
synapses to toxic molecules such as Aß. Consistent with
this view, various signaling pathways, which are crucial
for synapse integrity, undergo changes in the aging brain
(Bishop et al., 2010). Of particular interest is the Wnt
signaling pathway, which is required for synaptic plasticity
(McLeod et al., 2018), synaptic maintenance (Marzo et al.,
2016) and is altered during aging (Matarin et al., 2015;
García-Velázquez and Arias, 2017).
Wnt Signaling Deregulation in the Human
Aging Brain
A recent study showed that Wnt components expression
is affected in the aging human brain. Indeed expression
of Wnt ligands WNT2B, WNT6, and WNT7a and frizzled
receptors FZD2 and FZD3 is downregulated in the aged
human brain (Folke et al., 2018). Additionally, the same
study showed that the secreted frizzled-related protein 1
(SFRP1) is upregulated in the aged human brain (Folke
et al., 2018). Interestingly, SFRPs sequester Wnt ligands
in the extracellular space, thus increased SFRP1 could
interfere with many Wnt pathways. Together, these
findings suggest that Wnt signaling is dampened in the
aged human brain.
Dampening Wnt Signaling in the Aged
Rodent Brain
In the aged rodent brain, several Wnt pathway elements are also
downregulated. For example, the expression of the Wnt ligands
Wnt2, Wnt4, and Wnt9a, and transcription factors Lef1 and
Tcf3 is downregulated (Figure 2A; Hofmann et al., 2014). In
the dentate gyrus region of the hippocampus, Wnt3 and Wnt3a
expression progressively declines between 1 and 22 months
of age (Okamoto et al., 2011). Moreover, a specific reduction
in canonical Wnt signaling is evident in the hippocampus
of aged rats, where Dvl2, Axin2 and nuclear ß-catenin are
downregulated (Figure 2A; Orellana et al., 2015). A similar
deficiency in Wnt signaling is observed in a mouse model of
accelerated aging (Bayod et al., 2015). Reduced Wnt signaling in
the aging brain also arises from increased levels of endogenous
secreted Wnt antagonist such as Dickkopf-1 (Dkk1) in the
aging mouse brain (Figure 2A; Scott et al., 2013; Seib et al.,
2013). Altogether these data demonstrate a dampening of
Wnt signaling in the aging brain of rodents as not only
Wnt ligands and intracellular components of the pathway are
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FIGURE 1 | Wnt signaling pathways. (A) Canonical Wnt/ß-catenin pathway OFF: In the absence of Wnt binding to Frizzled (Fz) receptors and LRP5/6 co-receptors,
ß-catenin interacts with the destruction complex (CK1, GSK3β, Axin1 and APC), resulting in its phosphorylation by Gsk3ß and CK1 and its subsequent degradation
by the proteasome. (B) Canonical Wnt/ß-catenin pathway ON: When a Wnt ligand binds to LRP5/6 and Fz receptors, the scaffold protein Disheveled (Dvl) recruits
Axin1 and the kinases CK1 and GSK3ß to the membrane, disrupting the destruction complex and impairing ß-catenin phosphorylation and degradation. ß-catenin
accumulates in the cytoplasm and subsequently translocates to the nucleus, where it acts as an activator of TCF/LEF-mediated transcription of Wnt target genes.
(C) The Planar Cell Polarity (PCP) pathway: The PCP does not require LRP5/6 and is ß-catenin-independent. When Wnts bind to Fz receptors, Dvl is activated,
resulting in increased activation of ROCK and JNK through the small GTPases RhoA and Rac1, respectively. Changes in ROCK activity induce actin remodeling, and
JNK activation can promote gene transcription via Jun phosphorylation. The palmitate group in Wnt ligands is indicated as a yellow tail. CK1, casein kinase 1;
GSK3ß, glycogen synthase kinase 3β; Axin1, axis inhibition protein 1; APC, adenomatous polyposis coli; TCF, T-cell factor; LEF, lymphocyte-enhancer-binding factor;
Rock, Rho associated coiled-coil-containing protein kinase 1; RhoA, RAS homolog gene-family member A; JNK, Jun N-terminal kinase.
downregulated, but also the potent canonical Wnt antagonist
Dkk1 is upregulated.
Discrepancies Between the Human and
Rodent Aging Brain
Although Wnt signaling is reduced in both the human and
rodent aging brain, the specific deregulated Wnt signaling
components are not exactly the same (see above). A possible
explanation is that the studies have been conducted in
different areas of the brain, where Wnt components are
differentially expressed under basal conditions. For example,
most of rodent studies analyzed the hippocampus, whereas
human studies have been performed in the prefrontal
cortex. Nonetheless, the data presented showed that Wnt
signaling is reduced in the aging brain, possibly contributing
to the observed age-related synaptic decline (Morrison
and Baxter, 2012; Petralia et al., 2014). Thus, boosting
Wnt signaling in the aging brain may strengthen synaptic
resilience, slow down cognitive decline and decrease
the risk of pathological transitions toward dementia in
elderly individuals.
WNT SIGNALING AND
ALZHEIMER’S DISEASE
Deregulation of Wnt signaling may also contribute to synapse
vulnerability in the context of AD. Indeed, reduced Wnt signaling
has a direct impact on synapses (Marzo et al., 2016). In
addition, deficient Wnt signaling could also induce indirect
effects on synapses by activating the amyloidogenic pathway
(Liu et al., 2014) or by interfering with microglial survival
(Zheng et al., 2017).
Antagonizing Canonical Wnt
Signaling in AD
Several studies have shown that the canonical Wnt antagonist
Dkk1 is up-regulated in brains of AD patients and AD mouse
models (Caricasole et al., 2004; Rosi et al., 2010). Dkk1 inhibits
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FIGURE 2 | Wnt signaling deregulation in the aging brain and in AD. (A) Wnt signaling components are deregulated in both the aging and AD brain. Notably, the Wnt
antagonist Dkk1 is upregulated, whereas Wnt ligands, Dvl, ß-catenin, and TCF are downregulated, leading to decreased canonical Wnt signaling. (B) As Dkk1 mainly
affects the canonical Wnt signaling pathway, we propose a model by which elevation of Dkk1 results in an imbalance between the Wnt/ß-catenin and PCP
pathways, resulting in synaptic defects and synapse loss. (C) In the brain of AD subjects and AD mouse models, the Wnt antagonist Dkk1 is elevated, leading to
increased activity of both Gsk3ß and ROCK, thus resulting in reduced Wnt/ß-catenin signaling and increased PCP signaling. The activation of these two kinases
leads to synapse vulnerability but the precise mechanisms downstream remain to be defined. A possible mechanism is that tau phosphorylation and actin
remodeling contribute to synaptic changes (gray arrows and diffuse red boxes in the scheme) and subsequent cognitive deficits. These results suggest that
pharmacologically targeting Wnt signaling could be a promising therapeutic strategy for synapse protection in AD.
canonical Wnt signaling by interacting with LRP5/6 Wnt co-
receptors, thus impairing the binding of Wnt proteins to both
Frizzled and LRP5/6. This inhibition of Wnt signaling by Dkk1
leads to increased Gsk3ß activity and reduced cytoplasmic ß-
catenin levels – both features which are observed in the brains
of AD patients (Zhang et al., 1998; Pei et al., 1999; Kawamura
et al., 2001). In addition, Dkk1 expression is rapidly elevated by
Aß in hippocampal neurons, resulting in reduced canonical Wnt
signaling and concomitant synapse loss (Figure 2; Purro et al.,
2012; Sellers et al., 2018). Interestingly, synapses are protected
from Aß insult when Dkk1 is blocked, suggesting that Dkk1 is
required for Aß-mediated synapse loss (Purro et al., 2012). To
mimic the effect of Aß on synapses through Dkk1, a transgenic
mouse model was generated that inducibly expresses Dkk1 in
the brain (iDkk1 mice). Induced Dkk1 expression results in
synapse loss in the striatum (Galli et al., 2014) and hippocampus
(Marzo et al., 2016) without affecting cell viability. Moreover,
iDkk1 mice exhibit reduced synaptic transmission, impaired LTP
and enhanced LTD in the adult hippocampus, accompanied by
long-term memory deficits (Marzo et al., 2016). Thus, increased
expression of Dkk1 in the adult brain reproduces several of the
phenotypic aspects observed in AD models (Marchetti and Marie,
2011; Esquerda-Canals et al., 2017). Interestingly, a variant of the
Wnt/Dkk1 receptor LRP6, which displays reduced Wnt signaling
in cell lines, is associated with an increased risk for late-onset AD
(De Ferrari et al., 2007). This finding further strengthens the link
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between deficient Wnt signaling and AD. In addition, neuronal
deletion of LRP6 in the postnatal forebrain leads to synaptic
loss and exacerbates AD pathology in an AD mouse model (Liu
et al., 2014). Collectively, these results support the view that Aß-
induced inhibition of Wnt signaling through Dkk1 contributes to
synaptic impairment and cognitive deficits in AD.
Wnt Signaling Involvement in Aß
Production and Tau Tangles
Several additional lines of evidence further suggest that deficiency
in Wnt signaling contributes to AD pathogenesis. First, the
canonical co-receptor LRP6 modulates the processing of the
Aß precursor protein (APP) and knock-out of LRP6 leads to
increased Aß production in an AD mouse model (Liu et al.,
2014). This is further supported by in vitro studies showing
that suppression of canonical Wnt signaling or activation of the
Wnt-PCP pathway promotes the amyloidogenic processing of
APP, leading to increased production of Aß through a feedback
loop mechanism (Tapia-Rojas et al., 2016; Elliott et al., 2018).
In addition, several other Wnt pathway components, including
ß-catenin, Tcf4, Gsk3ß, and Dvl1, have been implicated in
modulating APP processing (Mudher et al., 2001; Liu et al.,
2014; Parr et al., 2015; Tapia-Rojas et al., 2016). Second,
reduced Wnt signaling leads to increased Gsk3ß activity,
which contributes to tau hyperphosphorylation (Scali et al.,
2006; Salcedo-Tello et al., 2014), a key pathological hallmark
of AD. Conditional overexpression of Gsk3ß in the brain
causes neurodegeneration and learning deficits (Hernández
et al., 2002). Collectively, this data suggests that reduced Wnt
signaling is involved in a negative feedback loop promoting
the exacerbation of AD pathology, which in turn would
dampen Wnt signaling further by Aß-mediated increase in
Dkk1 expression.
AD Associated Genes Are Linked to
Reduced Wnt Signaling
Several AD susceptibility genes (including APOE, TREM2,
and Clusterin) are linked to aberrant Wnt signaling. For
example, ApoE4, a major genetic risk factor for late-onset AD,
inhibits canonical Wnt signaling in cell lines (Caruso et al.,
2006). More recently, a study showed that TREM2, which
is linked to late-onset AD, promotes microglia proliferation
through Wnt signaling (Zheng et al., 2017). Finally, the AD-
associated protein Clusterin (Harold et al., 2009; Lambert
et al., 2009) is involved in Aß-driven Dkk1 expression, as
soluble Aß promotes the intracellular accumulation of Clusterin
and subsequent Dkk1 upregulation, whereas knock-down of
Clusterin prevents induction of Dkk1 expression and protects
against Aß neurotoxicity (Killick et al., 2014). Not only AD
risk factors are linked to reduced Wnt signaling. For example,
Wnt signaling promotes the expression of RE1-Silencing
Transcription factor (REST) during normal aging (Willert et al.,
2002; Lu et al., 2014). In turn, REST represses pro-apoptotic genes
and exerts a protective function against oxidative stress and Aß
neurotoxicity (Lu et al., 2014). Thus, diminished Wnt signaling
could contribute to reduced REST levels observed in AD (Lu
et al., 2014), resulting in increased susceptibility to Aß toxicity.
In summary, a growing body of evidence suggests that
Wnt signaling is deregulated in AD, which could contribute to
synapse degeneration and cognitive decline. This deficiency in
Wnt signaling may further exacerbate key pathological processes
including Aß production and Tau hyperphosphorylation.
PROTECTIVE EFFECTS OF WNT
SIGNALING AGAINST Aß
Activation or restoration of Wnt signaling has protective effects
in the context of Aβ-induced synaptic degeneration. Dkk1-
induced synapse loss, impaired synaptic plasticity and cognitive
defects can be fully reversed in vivo upon restoration of Wnt
signaling through the cessation of Dkk1 expression (Marzo
et al., 2016). In vitro, synapses can be protected against Dkk1
by inhibiting two kinases regulated by Wnt signaling: Gsk3ß
and ROCK (Figure 2C; Marzo et al., 2016). Consistently,
in vivo inhibition of Gsk3ß by the specific substrate-competitive
inhibitor L803-mts peptide improves cognition in AD mouse
models (Avrahami et al., 2013; Licht-Murava et al., 2016).
In addition, in vivo inhibition of ROCK by fasudil improves
cognition (Sellers et al., 2018) and reduces Aß load in AD rodent
models (Elliott et al., 2018; Figure 2C). These studies suggest that
Dkk1-induced synapse loss is reversible and mediated through
the inhibition of canonical Wnt signaling and the concomitant
activation of the Wnt/PCP pathway (Figure 2B).
Increased levels of Wnt ligands are particularly protective
against Aß-mediated cell toxicity. For example, exogenous Wnt3a
prevents Aß neurotoxicity in cell lines and cultured hippocampal
neurons (De Ferrari et al., 2003; Alvarez et al., 2004; Chacón
et al., 2008). Aß-induced synaptic damage is also alleviated by
Wnt5a in acute hippocampal slices, which prevents the dispersal
of postsynaptic clusters and protects against defects in excitatory
postsynaptic currents elicited by Aß (Cerpa et al., 2010). In
summary, a number of studies strongly suggests that restoring or
boosting Wnt signaling could protect cells and synapses from Aß
toxicity and ameliorate AD pathology.
POTENTIAL SIDE EFFECTS OF
BOOSTING WNT SIGNALING
Given the role of Wnts in cancer, the challenge is how to develop
treatments to boost Wnt signaling in neurodegenerative diseases
without promoting cancer. Mutations in several Wnt signaling
pathway components have been linked to colorectal cancer, in
particular loss of function mutations in APC leading to high levels
of active ß-catenin (Zhan et al., 2017). Also, transgenic models
overexpressing Wnt1, and inducing high levels of ß-catenin
activation, lead to mammary gland adenocarcinomas in mice
(Tsukamoto et al., 1988). In addition, in several other cancers in
which Wnt signaling plays a role, mutations in other oncogenic
genes are required (White et al., 2012). For example, active
ß-catenin levels are increased in a Pten knock-out hematopoietic
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stem cells induced T-lymphoblastic leukemia (T-ALL) mouse
model (Guo et al., 2008). In this T-ALL model, the primary
mutation is in the Pten gene, however, the ablation of one ß-
catenin allele decreases the incidence and delays the appearance
of the T-ALL (Guo et al., 2008). These studies suggest that high
levels of the canonical Wnt signaling are required for cancer and
that in many cases Wnt signaling activation is a secondary effect
of other oncogenic mutations. In addition, different preclinical
and clinical studies have tested GSK inhibitors as possible
therapies for Alzheimer’s disease and for different types of
cancer (Walz et al., 2017). Therefore, boosting Wnt signaling
in a regulated manner could provide a viable approach for the
treatment of neurodegenerative diseases without increasing the
incidence of cancer.
CONCLUSION
Compelling evidence supports the notion that Wnt signaling
is deregulated in the aging brain and in AD (Figure 2B).
Notably, the Wnt antagonist Dkk1 induces AD-related synaptic
loss and cognitive impairment. Further mechanistic insights are
required to elucidate how GSK3ß and ROCK activation lead
to synapse loss in a synergic way. One could postulate that
ROCK induces actin remodeling, which could lead to spine loss.
However, the role of GSK3ß is less clear. Interestingly, the closely
related protein Dkk3 is elevated in plasma and cerebrospinal
fluid of AD patients, however, its role in the adult brain is
still largely unexplored. In addition to Dkks, SFRPs represent
another class of endogenous Wnt antagonists, which inhibit Wnt
signaling by sequestering Wnt ligands. It is currently unknown
whether these antagonists are similarly deregulated in the aging
brain and in AD. Although two Wnt ligands are protective
against Aß-induced synaptotoxicity in cultured neurons, their
in vivo role has not been demonstrated. Moreover, we still lack
a comprehensive view of the expression and activity of other
Wnt ligands in the context of brain aging and AD. Further
studies on key Wnt components such as Wnt secreted factors
and Wnt receptors could provide more mechanistic insight into
how deregulation of Wnt signaling contributes to cognitive
decline during normal aging and in AD. Targeting components
of the Wnt signaling pathway could open therapeutic avenues for
boosting synaptic resilience and enhancing cognition in elderly
people and people living with AD.
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